EyePoint Pharmaceuticals was listed on Nasdaq, accompanied by rating updates from TD Cowen (downgrade) and Jefferies (upgrade).
1 report, 1 independent
Updated Sep 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
EyePoint Pharmaceuticals was listed on Nasdaq, accompanied by rating updates from TD Cowen (downgrade) and Jefferies (upgrade).
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
EyePoint Pharmaceuticals (United Kingdom)
company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery
Nothing else this week.
-
Nasdaq
American fully electronic stock exchange
-
TD Cowen
American investment bank
Related events
- Analyst firms Jefferies, TD Cowen, and Raymond James Financial provided rating updates for Black Diamond Therapeutics, alongside MarketBeat consensus data.
- Texas Roadhouse received multiple analyst rating and price target updates from Jefferies and TD Cowen, alongside stock listing information.
- Multiple financial firms, including TD Cowen, Goldman Sachs, and Mizuho, issued various rating changes and price target updates across several stocks.
- Analyst rating updates for Krystal Biotech, including a buy rating from TD Cowen and a consensus rating from MarketBeat.
- Financial firms, including RBC, TD Cowen, Leerink Partners, and Morgan Stanley, raised price targets and provided coverage for Vertex Pharmaceuticals.